Preclinical development of GD2 CAR-T cell therapy for glioblastoma /
Files
(Published version)
Date
2024
Authors
Yeo, Erica
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
thesis
Citation
Statement of Responsibility
Conference Name
Abstract
Glioblastoma is an aggressive brain tumour with low survival rates and limited treatment options. Chimeric antigen receptor (CAR)-T cell therapy is a promising approach, with GD2 identified as a potential target due to its high expression in tumours. This study validated GD2 as a target for glioblastoma and compared GD2 CAR-T cells generated using two culture protocols, assessing cytotoxicity against patient-derived tumour cells and 3D organoids, as well as proliferation, persistence, and tumour homing. CAR-T cells from the modified protocol showed a less differentiated state, slower but effective tumour cell killing, and improved tumour homing, potentially enhancing their survival and migration. These findings support GD2 CAR-T cell therapy as a promising glioblastoma treatment, though further optimization is needed for improved efficacy.
School/Discipline
University of South Australia. UniSA Clinical and Health Sciences.
UniSA Clinical and Health Sciences
UniSA Clinical and Health Sciences
Dissertation Note
Thesis (PhD(Medical Science))--University of South Australia, 2024.
Provenance
Copyright 2024 Erica Cai Fey Yeo.
Description
1 ethesis (xiii, 226 pages) :
colour illustrations, colour charts.
Includes bibliographical references (pages 177-196)
colour illustrations, colour charts.
Includes bibliographical references (pages 177-196)
Access Status
506 0#$fstar $2Unrestricted online access